FCCC-PENN SPORE in Ovarian Cancer

福克斯蔡斯癌症中心（FCCC）和宾夕法尼亚大学（PENN）卵巢孢子是作为两个费城NCI癌症中心之间的合作伙伴关系提交的，要求支持本孢子的11年至15年。在过去的9年里，SPORE计划已经成熟和发展。从今天的SPORE来看，新提交的显著区别是为SPORE招募了新的充满活力的领导层，带来了新的想法，技术和机构投资。这一翻译重点得益于SPORE计划的成熟度，机构对卵巢癌的研究深度，以及几乎独特的机构资源，这些资源促进了FCCC-PENN卵巢癌计划的扩展。在新的SPORE中有五个高度翻译的项目。这些项目包括：P1）基因甲基化特征用于治疗反应的预测分类; P2）改善BRCA 1/2携带者之间卵巢癌风险的估计和沟通以优化决策; P3）卵巢癌的治疗性微RNA策略; P4）通过新型RNAi方法靶向信号网络以改善卵巢癌的治疗; P5）推进卵巢癌的T细胞治疗。该计划由三个独立的核心支持，包括行政，生物标本和组织采购，以及生物统计学和生物信息学核心。SPORE还有一个非常有效的职业发展计划和一个发展试点项目计划，该计划成功地启动了许多初级调查员的职业生涯，并在SPORE的前十年中确定了新的项目。2004年至2014年期间，对SPORE和FCCC-PENN卵巢癌项目的投资来自对SPORE的直接投资（620万美元），另有1090万美元用于PENN和FCCC的卵巢癌项目和教师。此外，两个NCI癌症中心还提供了额外的1340万美元，用于支持妇科肿瘤临床和研究基础设施的相关重要投资。此外，在过去五年中，FCCC-PENN卵巢孢子研究产生了超过1000万美元的抵押品和后续赠款，从而使卵巢癌（但非孢子）对卵巢癌计划和基础设施的总投资超过4100万美元。

The Fox Chase Cancer Center (FCCC) and the University of Pennsylvania (PENN) Ovarian SPORE is submitted as a partnership between two Philadelphia NCI Cancer Centers requesting support for years 11 through 15 of this SPORE. Over the last 9 years the SPORE program has matured and evolved. Viewing the SPORE today, the notable difference in the new submission has been the recruitment of new and energetic leadership to the SPORE bringing new ideas, technologies, and institutional investment. This translational focus is a benefit of both the SPORE Program's maturity, the depth of research in ovarian cancer at the institutions, as well as nearly unique institutional resources that catalyzed the expansion of the ovarian cancer program at FCCC-PENN. Within the new SPORE are five highly translational Projects. The projects include: PI) Gene Methylation Signatures for Predictive Classification of Response to Therapy; P2) Improving the Estimation and Communication of Ovarian Cancer Risk among BRCA1/2 Carriers to Optimize Decision Making; P3) Therapeutic Micro RNA Strategies for Ovarian Cancer; P4) Targeting Signaling Networks via Novel RNAi Approaches to Improve Therapy for Ovarian Cancer; P5) Advancing T cell Therapy for Ovarian Cancer. The Programs are supported by three separate cores including an Administrative, Biospecimen and Tissue Procurement, and a Biostatistics and Bioinformatics Cores. The SPORE also has a highly effective Career Development Program and a Developmental Pilot Project Program which has been successful at launching the career of many junior investigators and has served to identify new Projects through the first ten years of the SPORE. The investment in the SPORE and the FCCC-PENN Ovarian Cancer Program between 2004 and 2014 comes through direct investments in the SPORE ($6.2 million), with another $10.9 million into the ovarian cancer programs and faculty at PENN and FCCC. In addition, the two NCI Cancer Centers have provided an additional $13.4 million in associated yet important investments supporting the gynecologic oncology clinical and research infrastructure. In addition, over 10 million dollars in collateral and follow on grants have been generated from FCCC-PENN Ovarian SPORE research in the last five years thus bringing the total ovarian cancer (but non-SPORE) investment into the ovarian cancer programs and infrastructure to over 41 million dollars.